Valeant Pharmaceuticals

Allergan Fined $15M Over Disclosure Failures
Risk & Compliance

Allergan Fined $15M Over Disclosure Failures

The SEC says the drug maker failed to timely inform investors about its merger talks with Salix and Actavis.
By Matthew Heller | January 18, 2017
Read More
Ex-Valeant, Philidor Execs Accused of Kickback Scheme
Risk & Compliance

Ex-Valeant, Philidor Execs Accused of Kickback Scheme

The defendants “illegally converted Valeant shareholder money into their own personal nest eggs," a federal prosecutor alleges.
By Matthew Heller | November 18, 2016
Read More
Regulator Bars Valeant Officers From Trading
Risk & Compliance

Regulator Bars Valeant Officers From Trading

A Canadian regulator issues a cease trade order after the troubled drug maker announces it would be late filing financial reports.
By Katie Kuehner-Hebert | April 1, 2016
Read More
Ex-Valeant CFO Denies ‘Improper Conduct’
Risk & Compliance

Ex-Valeant CFO Denies ‘Improper Conduct’

Howard Schiller says he is not to blame for the incorrect recognition of $58 million in revenue that has caused Valeant to restate its financial results.
By Katie Kuehner-Hebert | March 21, 2016
Read More
Valeant Stock Falls 10% on News of CEO’s Illness
People

Valeant Stock Falls 10% on News of CEO’s Illness

Michael Pearson, who was hospitalized with pneumonia, has been trying to win back investor trust amid concerns over Valeant's pricing practices.
By Katie Kuehner-Hebert | December 28, 2015
Read More
Valeant to Take $150M Hit From Walgreens Deal
Supply Chain

Valeant to Take $150M Hit From Walgreens Deal

Valeant's revenue hit will include the value of the drugs shifted to consignment status and expected delays recognizing revenue from the Walgreens deal.
By Matthew Heller | December 23, 2015
Read More
Activist Investor Can’t Dodge Insider Trading Suit
Risk & Compliance

Activist Investor Can’t Dodge Insider Trading Suit

A judge finds Bill Ackman can be sued for allegedly buying a stake in Allergan based on inside information about a takeover bid by Valeant Pharmaceuticals.
By Matthew Heller | November 12, 2015
Read More
Zoetis Gives Back Post-Takeover Report Gains
Strategy

Zoetis Gives Back Post-Takeover Report Gains

Shares in the animal-health giant take a rollercoaster ride after a report of a possible acquisition by Valeant Pharmaceuticals.
By Matthew Heller | June 26, 2015
Read More
Watchdogs Call for Shorter Window for Activist Disclosures
Risk

Watchdogs Call for Shorter Window for Activist Disclosures

Groups say loopholes in securities laws allow activist investors to secretly buy large stakes in companies before initiating hostile takeovers.
By Katie Kuehner-Hebert | April 17, 2015
Read More
Salix Calls Off Tax Inversion Deal
Tax

Salix Calls Off Tax Inversion Deal

The Treasury Department's recent anti-inversion measures claim their first victim — Salix Pharmaceuticals' plan to merge with Italy-based Cosmo.
By Iris Dorbian | October 3, 2014
Read More